Acute myeloid leukaemia
RecruitingStudy comparing venetoclax with intensive chemotherapy (daunorubicin, cytarabine, gemtuzumab ozogamicin) in patients with favorable risk acute myeloid leukemia
Study comparing venetoclax with intensive chemotherapy (daunorubicin, cytarabine, gemtuzumab ozogamicin) in patients with favorable risk acute myeloid leukemia
- Disease:Acute myeloid leukaemia
- Substances:CytarabineVenetoclax+2
Denmark- Participants:18–64 years · 65+ years
- Substances:Cytarabine
- Sponsor:The University Of Birmingham












